t**u
发帖数: 1572 | 1 http://seekingalpha.com/article/286770-dendreon-s-plunge-no-sho
Dendreon (DNDN) shares have been absolutely decimated in the past month,
with shares falling almost 75% from $40 at this point last month to $10.37
as of this writing. The majority of the loss came as the market digested the
company's latest disastrous earnings report, which included a huge revenue
miss and a removal of the company's previous revenue guidance. Analysts
punished the company with a wave of downgrades, and the stock co... 阅读全帖 |
|
O****L
发帖数: 3353 | 2 Dendreon Announces Offering of $500 Million Convertible Senior Notes Due
2016
SEATTLE, Jan. 13, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN)
today announced its intention to offer, subject to market and other
conditions, $500 million aggregate principal amount of convertible senior
notes due January 15, 2016 (the "Notes") in an offering registered under the
Securities Act of 1933, as amended (the "Securities Act"). The Notes will
be convertible into cash, shares of Dendreon's common... 阅读全帖 |
|
v**********m
发帖数: 5516 | 3 由于这个？
Dendreon Agrees to Sell VICTRELIS(TM) (boceprevir) Royalty Interest for $125
Million
SEATTLE, Dec 06, 2011 (BUSINESS WIRE) -- Dendreon Corporation DNDN -0.11%
today announced that it has agreed to sell for $125 million in cash its
royalty interest related to intellectual property licensed to Schering-
Plough Ltd. and Schering Corporation (collectively Schering, each now a
wholly owned subsidiary of Merck & Co., Inc.) and associated with VICTRELIS(
TM) (boceprevir), a treatment for chronic... 阅读全帖 |
|
y*****l
发帖数: 5997 | 4 大盘大跌 + debt ceiling + DNDN大跌.
How Dendreon Can Fix Its Broken Relationship With Wall Street
By David Miller Aug 04, 2011 20:00 pm
http://www.minyanville.com/businessmarkets/articles/health-care
Dendreon (DNDN) is down hugely this morning on last night's earnings miss
and guidance rescission. The NASDAQ Biotech Index (^NBI) and associated ETF
(IBB) are down also. This is not a good day for the biotech sector, as the
reimbursement issues faced by Dendreon seem, at the 10,000-foot level, to
fit wit... 阅读全帖 |
|
j*****7
发帖数: 4348 | 5 【 以下文字转载自 Stock 讨论区 】
发信人: jhsph07 (银杏), 信区: Stock
标 题: 你炒股票， FA做得在漂亮， 怎么搞得过这些人呢
发信站: BBS 未名空间站 (Thu Jul 9 17:22:47 2009, 美东)
当年(2007)搞DNDN的扑的就有这些大＂牛＂人啊！
As we know, only ten hedge funds on the planet owned large numbers of
Dendreon put options at the end of March 2007, right after Dendreon received
the fantastic news that the FDA’s advisory panel had voted that the
company’s treatment for prostate cancer should be approved. In other words,
after Dendreon received its fantastic news only ten h... 阅读全帖 |
|
O**I
发帖数: 776 | 6 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
O**I
发帖数: 776 | 7 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 8 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
w*********7
发帖数: 2883 | 9 Faruqi & Faruqi, LLP Announces Investigation of Dendreon Corp.
11 minutes ago - BIZ via Comtex
BusinessWire
Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights,
consumer rights and enforcement of federal antitrust laws, is investigating
potential wrongdoing at Dendreon Corp. ("Dendreon" or the "Company") (NASDAQ
federal securities laws in connection with statements made to the Company's
shareholders.
Request more information now by clicking here: www.faruqilaw.com/DNDN
Spe... 阅读全帖 |
|
R******a
发帖数: 1195 | 10 Shares of Dendreon (NASDAQ: DNDN) saw increased strength during Tuesday's
early morning trading session as investors bid up shares on further
speculation that the company may be in the works of selling itself.
There were rumors spreading on Twitter that Celgene (NASDAQ: CELG) could be
looking to acquire Dendreon. Ian Estepan @ianestepan said, "There is nothing
stronger than the hope trade... $CELG for $DNDN making the rounds again..."
any comment on this rumor?
A couple analysts that Benzinga sp... 阅读全帖 |
|
S*********n
发帖数: 3939 | 11 袁亚非疯狂并购后遗症 三胞400亿债务危机终爆发
大摩财经 2018-07-30
曾大举在海外并购的三胞集团，终于也到了爆雷时刻。
7月23日至今，三胞集团先是债券大跌后停牌，然后被曝出融资资管计划公开违约、被
法院列入执行人名单，信用等级下调，陷入流动性危机。
三胞集团是江苏南京的明星企业，旗下多家上市公司，近年来资本运作颇为频繁。三胞
集团的核心是投资控股，自2014年起，其先后在国外收购英国百货公司HoF、美国零售
品牌Brookstone、生物医药公司Dendreon等公司；三胞集团在国内还先后收购拉手网、
麦考林、乐语通讯等公司。
三胞集团的危机在今年6月已有先兆。三胞集团旗下上市公司南京新百（600682.SH）自
6月21日起，连续8个交易日跌停，股价惨遭腰斩。另一家核心上市公司宏图高科（
600122.SH）自6月15日起则以重大重组名义停牌。
三胞集团持有宏图高科21.46%、南京新百27.32%的股权，为实际控制人。为了增强市场
信心，三胞集团实控人（持股97.5%）袁亚非今年2月还向市场承诺半年内将增持宏图高
科，结果到了7月增持也还没有进展。
由于资金紧张，三胞... 阅读全帖 |
|
O****L
发帖数: 3353 | 12 A Medicare advisory panel is scheduled to vote tomorrow on whether to accept
Dendreon Corporation's (NASDAQ:DNDN) prostate cancer drug, Provenge. The
fate of the company - and certainly its stock price - hangs (in the near
term) in the balance of this decision. While the panel is supposed to
consider only whether Dendreon has produced sufficient evidence proving that
Provenge extends patients' lives, many have doubted approval based on the
price tag.
The drug, Dendreon's only product, costs a wh... 阅读全帖 |
|
n*********e
发帖数: 25274 | 13 The share price of biotech firm Dendreon (DNDN) plunged on Tuesday after the
company released its second-quarter earnings results and announced a
restructuring plan that will trim 600 jobs. In afternoon trading, Dendreon
was down around 23%. The company hit a new 52-week low earlier in the
session at $4.75.
The strategic restructuring will cut 600 jobs, or 41% of the company's
workforce. Under the plan, Dendreon's Morris Plains, N.J., facility will be
closed. The restructuring is projected to re... 阅读全帖 |
|
f**********g
发帖数: 2252 | 14 Dendreon and ADVENTRX Present Promising Pipelines
1 hours 36 minutes ago - Marketwire via Comtex
MarketwireCancer is projected to become the leading cause of death worldwide
this year by the World Health Organization, and has already emerged as the
most expensive disease -- costing the global economy nearly a trillion
dollars a year. With cancer drugs alone costing the United States more than
$30 million a year, it is clearly a lucrative sector for drug makers. The
Bedford Report examines the ou... 阅读全帖 |
|
p********e
发帖数: 1960 | 15 DNDN, KERX, BPAX, CHTP, OPXA
http://seekingalpha.com/article/286963-5-cheap-biotech-stocks-t
Most biotech stocks have experienced very sharp drops as the markets have
plummeted over economic concerns. However, biotechs are not as economically
sensitive as other companies and therefore are likely to rebound sharply in
the coming days. These dirt cheap biotech companies all have interesting
products in the pipeline which could become major catalysts in the future.
The lower priced stocks tend to h... 阅读全帖 |
|
c*****l
发帖数: 739 | 16 Dendreon has been one of the worst-performing biotech stocks over the last
two years amid reimbursement issues for its Provenge prostate cancer drug
and other problems, but Bernstein said Friday that interviews with the drug
’s “busiest prescribers” showed they are not only increasing their use
but recruiting others to use the product as well. With that, Bernstein
forecasted “slow but steady revenue growth” for Dendreon and said it sees
signs the “progressive disaster” at the company could be co... 阅读全帖 |
|
y****o
发帖数: 666 | 17 烙印枪手在sa上pump
Availability of Provenge in Europe will drive Dendreon’s sales higher.
The approval of the automation process will help Dendreon improve margins
and grow sales.
The market for prostate cancer is expected to grow at a good pace, giving
Dendreon room for growth. |
|
c******a
发帖数: 267 | 18 嗯，既然这次讨论的是肿瘤免疫，我的专业，而且drp说得很好，我也想说两句。
我也看了这片文章，问了一下我们医院实验室的一个fellow(他已经做完了三年的
residency,是美国top10的MD/PhD)，他的意见是，I don't know how they can
publish it on NEJM with only 1 patient response out of total 3. They must
have very good relationship with the editor.
我的看法，首先，chimeric antigen receptor CAR这个概念一点都不新鲜，
preclinical已经做了很多年。但是几乎所有的实验到了clinical trial都失败了。主
要问题是回输的T cell到了病人体内好像细胞毒功能和增殖都变得很弱。但是这次的实
验是chemotherapy和immunotherapy联用，可能chemotherapy杀死了很多肿瘤细胞，这
些死亡或者损伤的肿瘤细胞变得容易被T cell识别和杀灭。作者在讨论里也提及这种可
能。在... 阅读全帖 |
|
d*****c
发帖数: 23 | 19 有人hold吗？公司的研发还在继续，Multikine的三期可能快开始了。
我转封CVM头的信。现在股价短期适中。
－－－－－－－－－
CEL-SCI Corporation Releases Letter to Shareholders
VIENNA, VA, July 7, 2009 – The following letter is being released by CEL-
SCI Corporation (NYSE AMEX: CVM) to its shareholders:
Dear Fellow Shareholders:
Recently we have been hearing a great deal about the pandemic caused by the
H1N1 swine flu. You may think to yourself, this is no big deal since it
does not seem that serious and, look what happened to bird flu - it
disappear... 阅读全帖 |
|
g******0
发帖数: 1165 | 20 Mark T. writes, "Thank you for all your wonderful insight into Cell
Therapeutics(CTIC). I was able to make some money on this stock because of
your input. On another note, I am invested now in Celldex Therapeutics(CLDX)
. Have you ever written about them? Can you provide us with some of your
insight here? Is it the next Dendreon(DNDN)?"
Celldex's lead drug, CDX-110, is a cancer immunotherapy (so, a cancer "
vaccine" cousin to Dendreon's Provenge) targeting glioblastoma multiforme (
GBM) aka brai... 阅读全帖 |
|
y*****l
发帖数: 5997 | 21 每人提可能做假账？大家对这个怎么看，问题不大的话值得捞。
http://finance.yahoo.com/news/Kahn-Swick-amp-Foti-LLC-bw-164189
Press Release Source: Kahn Swick & Foti, LLC On Wednesday August 3, 2011, 10
:55 pm
NEW ORLEANS--(BUSINESS WIRE)-- The law firm of Kahn Swick & Foti, LLC (“KSF
”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti,
Jr., announce the commencement of an investigation into Dendreon Corp. (“
Dendreon” or the Company)(Nasdaq:DNDN - News) to determine whether it has
violated federal securit... 阅读全帖 |
|
c***s
发帖数: 70028 | 22 树突细胞
当细胞毒T细胞上的PD-1分子与抗体结合时，免疫细胞能够识别肿瘤细胞，从而对其进行杀伤，图片节选自Nature Video
30日，美国洛克菲勒大学的免疫学家和细胞生物学家拉尔夫·斯坦曼（Ralph Steinman）罹患胰腺癌逝世。
未料，3天后，诺贝奖委员会宣布斯坦曼获得当年生理学或医学奖一半的奖金，以表扬他“发现树突状细胞和其在后天免疫中的作用”。因诺贝尔委员会维持授奖的决定，斯坦曼成为史无前例的唯一一位过世后获诺贝尔奖的学者。
斯坦曼是树突细胞(Dendritic Cell，树突状细胞，简称DC细胞)的最早发现者，晚年致力于基于树突细胞的肿瘤疫苗的研发。他还利用自己研发的疫苗成功地将生命延长了4年，原本他生命最后的时间被医生认为只有一年。
这种方法与魏则西最后接受的DC-CIK疗法类似。
事实上，斯坦曼生前也知道，该疗法对有些人有效，而对另一些则可能无效。所以利用该疗法治疗肿瘤患者，需要加以选择。
DC-CIK疗法的原理是什么，是否如一些医院大肆宣扬的那般有效？实际临床治疗又存在哪些问题？如何理性看待远未成熟的免疫治疗技术？《知识分子》就此专访了清华大学医学院千人计划... 阅读全帖 |
|
O****L
发帖数: 3353 | 23 Dendreon Pricing Comes in Higher-than-Expected
Dendreon Corporation (DNDN, Free Analysis), a biotechnology company focused
on cancer treatments, saw its shares jump sharply higher in early trading
after confirming approval of Provenge by the FDA and saying that its pricing
point would be around $93,000 annually, which is much higher than many
analysts were expecting.
As a result, some analysts are projecting hefty profits for the biotech firm
, ranging from $1.1 billion in 2014 to $4.3 billion b |
|
|
w****a
发帖数: 12 | 25 Biotech Calendar: 2011 FDA Drug Approvals
05/25/11
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advisory panels is also included.
Optimer Pharmaceuticals(OPTR_)
Drug/indication: Dificid for Clostridium difficile infection
FDA approval decision date: May 30, 2011
GlaxoSmithKline(GSK_) and Valeant Pharmaceuticals(VRX_... 阅读全帖 |
|
l*********1
发帖数: 517 | 26 NEW YORK (Dow Jones)--Dendreon Corp. (DNDN) said sales of its controversial
prostate cancer drug Provenge are growing slower than expected because
doctors aren't comfortable with the complex task of getting reimbursed for
the expensive treatment. As a result, the Seattle drug maker withdrew its
sales expectations for the year and announced plans to cut jobs. Shares of
Dendreon fell 62% to $13.66 in after-hours trading Thursday. |
|
f****X
发帖数: 64 | 27 DNDN的问题很复杂， Matthew Herper的这篇文章很值的参考一下
How many patients actually want to take Provenge, and how many doctors want
to prescribe it?
No one has a good answer.
The new problem facing Provenge, which Dendreon is calling “cost density,”
would certainly explain what went wrong in the quarter. Not only is
Provenge very expensive ($93,000 per patient), but doctors must outlay all
this cost themselves until Medicare or insurance companies pay them back.
David Miller of Biotech Stock Research, a longtime... 阅读全帖 |
|
m******7
发帖数: 25 | 28 以前老板夫妇回欧洲度假，和他们见了一面，老两口80多了，说到研发依然激情四溢。
他们年轻时候算是少有的坚信肿瘤免疫的几个，论文发的很牛。后来去美国进了业界，
一发不可收拾。虽然现在主业已经是投资人了，依然每天去在UW的实验室工作，依旧发
论文。他们认为在生物制药界，只要有好的，可以实用的技术，还是很有机会成功的。
举两个例子：
Dendreon,作为第一个FDA批准的cell therapy，一度大红大紫，股票涨到50刀以上，不
过现在一落千丈。他们的疗法只能延长4个月左右的晚期前列腺癌患者生命，而且只是
stable disease。他们提到一个很有趣的现象，Dendreon的CEO在股票暴涨后甩卖自己
的股份，然后买了豪宅和法拉利，说明他自己对这个技术其实就不怎么自信(我最喜欢
挺这种八卦了)。
Seattle genetics，他们是投资人，现在虽然经济不好，利润还是非常可观。lease
out了自己的一个技术给Genentech，就是一个linker，可以把chemo药和herceptin连在
一起然后靶向给药。
他们目前很感兴趣的一个小公司，两个以前在nobel laurea... 阅读全帖 |
|
|
y*****l
发帖数: 5997 | 30 Stocks to Watch at JPMorgan Healthcare Conference
By David Miller Jan 07, 2011 3:00 pm
Next week investors will congregate in California to discuss the future of
the biotech industry. Companies to watch include Exelixis, Medivation, and
Dendreon.
It’s the time of year for the JPMorgan (JPM) Healthcare Conference. The
conference, which runs Monday through Thursday next week in San Francisco,
is the surest place to see everyone in biotech each year. The size of the
crowd at the conference, held at... 阅读全帖 |
|
y*****l
发帖数: 5997 | 31 Stocks to Watch at JPMorgan Healthcare Conference
By David Miller Jan 07, 2011 3:00 pm
Next week investors will congregate in California to discuss the future of
the biotech industry. Companies to watch include Exelixis, Medivation, and
Dendreon.
It’s the time of year for the JPMorgan (JPM) Healthcare Conference. The
conference, which runs Monday through Thursday next week in San Francisco,
is the surest place to see everyone in biotech each year. The size of the
crowd at the conference, held at... 阅读全帖 |
|
v**********m
发帖数: 5516 | 32 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
v**********m
发帖数: 5516 | 33 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
w*******0
发帖数: 13 | 34 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 35 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 36 http://www.thestreet.com/story/11016605/1/biotech-calendars-201
By Adam Feuerstein 02/22/11 - 07:36 AM ES
Stock quotes in this article:HGSI, OPTR, XNPT, SPPI, DRRX, PATH
BOSTON (TheStreet) -- I've updated the 2011 FDA drug approval calendar.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regul... 阅读全帖 |
|
y*****l
发帖数: 5997 | 37 http://www.thestreet.com/story/11131722/1/biotech-calendar-2011
Biotech Calendar: 2011 FDA Drug Approvals
By Adam Feuerstein 05/25/11
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated.
For easier reference, this regulatory calendar is organized in chronological order based on the drug approval decision date. Information on pending FDA advisory panels is also included.
Optimer Pharmaceuticals(OPTR_)
Drug/indication: Dificid for Clostridium difficile infection
FDA approval... 阅读全帖 |
|
y*****l
发帖数: 5997 | 38 http://www.thestreet.com/story/11131722/1/biotech-calendar-2011
Stock quotes in this article:SPPI, CTIC, TSPT, SGEN, ANX, PATH, OPTR
http://finviz.com/screener.ashx?v=341&t=SPPI,CTICD,TSPT,SGEN,AN
Biotech Calendar: 2011 FDA Drug Approvals
By Adam Feuerstein 05/25/11
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advis... 阅读全帖 |
|
g****r
发帖数: 306 | 39 "We anticipate the positive National Coverage Determination (NCD) and Q-code
will have a significant impact on increased physician adoption. However, we
believe this will take time" --- uncertainty
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
"Accordingly, Dendreon is withdrawing its previous guidance of $350-400
million in revenue for 2011." --- lowered revenue outlook
"Dendreon's total operating expenses for the six months ended June 30, 2011
were $236.5 million compared to $126.1 million for the s... 阅读全帖 |
|
v**********m
发帖数: 5516 | 40 http://investor.dendreon.com/releasedetail.cfm?ReleaseID=620325
PLEASE click the weblink above to see the whole story.
DENDREON CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
Three Months Ended
September 30, Nine Months Ended
September 30,
2011 2010 2011 2010
(unaudited) (unaudited)
Revenue $64,287 $20,219 $139,468 $23,050
Cost of revenue 54,978 12,433 ... 阅读全帖 |
|
s*********e
发帖数: 462 | 41 药不是普通的商品，天朝的产品纯度不够，还是会有很大问题。 现在表面的原因是FDA
，举个例子，有一个遗传疾病，目前没有药物上市，美国有三家在临床，一家已经被否
，另一家在欧洲已经上市而且有疗效，但是FDA驳回了他的申请，这在药物申请的历史
上是罕见的，最后一家只做了2期，才11个病人，结果这家忽悠了一些病人家属三天两
头去FDA闹，现在弄得FDA不敢否，就拖在那里。如果要追究深层次的原因，又要指向花
街了，因为都是有股票上市的。类似的例子数不胜数，其实有效的药物被否，几十亿打
了水漂，其实没什么效果的安慰剂能上市，最后病人不买账，还是破产的命，比如
dendreon.这些瞎折腾的费用最后都要算进药价的！归根结底一句话，美国的根源就是
贪婪的食利族，比如巴菲和索罗斯这些老东西，现在gates也已经学会了！ |
|
V**D
发帖数: 2869 | 42 Immunotherapy 治疗肿瘤费用昂贵，有些效果也不是太理想。像dendreon生产的治疗前
列腺癌的产品，只能延缓半年左右的生命，其实治疗意义根本不大。 |
|
x*******l
发帖数: 542 | 43 5块钱的时候没看到你买
focused
pricing
firm
Dendreon
even |
|
c*******r
发帖数: 6971 | 44 你第一把已经扔了？
focused
pricing
firm
Dendreon
even |
|
|
|
l*****u
发帖数: 180 | 47 After market +2.7% to 36.43 le, good call.
Dendreon Corp. (NASDAQ: DNDN) 2.7% HIGHER; will host a conference call
tomorrow morning (9AM) to provide updates on U.S. commercialization progress
, European strategy for PROVENGE, and pipeline progress. |
|
|
w****r
发帖数: 245 | 49 大侠，分类都分好了，求神签
# Basic Materials, Agricultural Chemicals
AGU Agrium Inc.
AVD American Vanguard Corp.
CAGC China Agritech Inc.
CF CF Industries Holdings, Inc.
CGA China Green Agriculture, Inc.
CMP Compass Minerals International
COIN Converted Organics Inc.
IPI Intrepid Potash, Inc.
MON Monsanto Co.
MOS Mosaic Co.
NOEC New Oriental Energy & Chemical
POT Potas... 阅读全帖 |
|
y**a
发帖数: 143 | 50 DNDN AH trading is pretty active. PPS is only up 2%. Tomorrow will be an
interesting day. |
|
